Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2019

View Archived Issues

Identification of PDE10A inhibitors with potential application in schizophrenia

Phase III data demonstrates equivalence between SB8 and bevacizumab in terms of best ORR

Shanghai Fochon Pharmaceutical, Fochon Pharmaceuticals patent TRK inhibitors

Development of novel sclerostin-resistant mouse model of T1D

Symphogen presents early clinical data for Sym-015 in advanced solid tumors

Results presented from phase III SANET-ep study of surufatinib

First-in-human study of apramycin

GlaxoSmithKline initiates phase I study of GSK-2904545A vaccine candidate

CAR-iNKT cells safe and active in neuroblastoma patients

Preclinical results for IKS-01, a next-generation ADC with antitumor activity

Escalier Biosciences describes new RORgammaT modulators

Mavupharma presents E-NPP1 inhibitors

Peptide Logic awarded NIH HEAL initiative grant

New GBP1 and/or GBP1/PIM1 interaction inhibitors discovered at Stanford University

Arbutus Biopharma patents HBsAg secretion inhibitors

Keeping score by DRUP, not in dribs and drabs

Shire Human Genetic Therapies presents new kallikrein B inhibitors

Main function of Parkinson's gene is in inflammation

FDA approves Aklief cream for topical treatment of acne

GSK begins first-in-human study of rabies vaccine GSK-3903133A

Positive phase II data presented for lurbinectedin in malignant pleural mesothelioma

ReveraGen presents 18-month data on vamorolone in Duchenne muscular dystrophy

Kodiak begins phase II study of KSI-301 for wet AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...